Glaxo Diabetes Drug Will Face SB's Avandia; Anti-Herpetic Divestment Likely
Glaxo Wellcome intends to compete in the diabetes market with SmithKline Beecham's Avandia, Glaxo Chairman Richard Sykes indicated at an analysts earnings conference Feb. 16.
You may also be interested in...
Glaxo Wellcome will respond to an FDA "approvable" letter for the asthma product Advair Diskus by Feb. 18, Chairman Richard Sykes indicated during a Feb. 16 analysts conference.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011